Research Article - Archives of General Internal Medicine (2025) Volume 9, Issue 5

Comparative efficacy of duloxetine, gabapentin, and pregabalin in long-term diabetic neuropathy management.

Numerous millions of individuals worldwide have excruciating diabetic peripheral neuropathy. The FDA has officially approved pregabalin and duloxetine hydrochloride as treatments for painful diabetic peripheral neuropathy. It is generally established that as individual therapeutic drugs, duloxetine, pregabalin, and gabapentin are safe for treating uncomfortable diabetic peripheral neuropathy. We evaluated the effectiveness, side effects, and tolerability of duloxetine to those of pregabalin and the often-recommended duloxetine-gabapentin combination treatment in this literature article. To compare these three presently used medications statistically, we examined several sources, including PubMed, Science Direct, AAFP Articles, Medscape, Cochrane Library, Cureus, Medline Plus, and a few other databases. Duloxetine or pregabalin are used as alternative treatments when a patient is not responding well to gabapentin. Which alternative would be best for the patient is still unclear. It is preferable to use duloxetine, which belongs to a distinct class of medications if a patient is on another anticonvulsant. Pregabalin is a preferable option if the patient is taking an antidepressant to avoid serotonin syndrome. This literature evaluation compares these three medications for the management of uncomfortable diabetic peripheral neuropathy.

Author(s):

Athira Nair*, Manoj Pallapothu, Rithish Nimmagadda, Vamsi Polepalli, Anuja Nandanapu, Shravya Edavaluru, Juber Shaikh

Abstract PDF